Investments will be used for the clinical trial and product development.
Basic development including preclinical trial and
proof-of-concept human testing has been done.
The company has completed two clinical trials where the biomarker was discovered. The first study included 24 subjects whereas the second contained 69. The recruitments were carried out in three Finnish
hospitals; Tyks, Satakunta Central Hospital, Vaasa Central Hospital.
Currently the company is running a third
clinical trial to validate the biomarker in children who have suffered a
concussion. The sample collection from 29 TBI and 30 healthy subjects is completed, and the samples are currently being analyzed for the presence of the biomarker.